JP2024524534A - 炎症性疾患及び自己免疫疾患の治療のための修飾il-2ポリペプチド - Google Patents

炎症性疾患及び自己免疫疾患の治療のための修飾il-2ポリペプチド Download PDF

Info

Publication number
JP2024524534A
JP2024524534A JP2024500133A JP2024500133A JP2024524534A JP 2024524534 A JP2024524534 A JP 2024524534A JP 2024500133 A JP2024500133 A JP 2024500133A JP 2024500133 A JP2024500133 A JP 2024500133A JP 2024524534 A JP2024524534 A JP 2024524534A
Authority
JP
Japan
Prior art keywords
modified
polypeptide
seq
amino acid
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524534A5 (cg-RX-API-DMAC10.html
Inventor
クレフト,ベルトルト
パタタビラマン,ウィジャヤ,ラーガヴァン
サンチェス,ルーベン アルバレス
ミュラー,マガリ
キャラロット,ジャン-フィリップ
Original Assignee
ブライト ピーク セラピューティクス エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブライト ピーク セラピューティクス エージー filed Critical ブライト ピーク セラピューティクス エージー
Publication of JP2024524534A publication Critical patent/JP2024524534A/ja
Publication of JP2024524534A5 publication Critical patent/JP2024524534A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2024500133A 2021-07-09 2022-07-09 炎症性疾患及び自己免疫疾患の治療のための修飾il-2ポリペプチド Pending JP2024524534A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163219995P 2021-07-09 2021-07-09
US202163219989P 2021-07-09 2021-07-09
US63/219,989 2021-07-09
US63/219,995 2021-07-09
PCT/IB2022/056367 WO2023281485A1 (en) 2021-07-09 2022-07-09 Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2024524534A true JP2024524534A (ja) 2024-07-05
JP2024524534A5 JP2024524534A5 (cg-RX-API-DMAC10.html) 2025-07-16

Family

ID=82701753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500133A Pending JP2024524534A (ja) 2021-07-09 2022-07-09 炎症性疾患及び自己免疫疾患の治療のための修飾il-2ポリペプチド

Country Status (7)

Country Link
US (2) US12173062B2 (cg-RX-API-DMAC10.html)
EP (2) EP4367132A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024524534A (cg-RX-API-DMAC10.html)
KR (1) KR20240034221A (cg-RX-API-DMAC10.html)
AU (1) AU2022306974A1 (cg-RX-API-DMAC10.html)
CA (1) CA3222357A1 (cg-RX-API-DMAC10.html)
WO (2) WO2023281483A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515778A (ja) * 2009-01-21 2012-07-12 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2020521452A (ja) * 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
WO2020236875A1 (en) * 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
WO2020242884A1 (en) * 2019-05-24 2020-12-03 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
WO2021011353A1 (en) * 2019-07-12 2021-01-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
WO2021021606A1 (en) * 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
JP2021505156A (ja) * 2017-12-06 2021-02-18 パンディオン・オペレーションズ・インコーポレイテッド 標的化免疫寛容
WO2021076805A1 (en) * 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
US20210155665A1 (en) * 2017-07-24 2021-05-27 Eth Zurich Method for preparing interleukin-2 or interleukin-2 analogues

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
JP5275566B2 (ja) 2003-06-18 2013-08-28 ザ スクリプス リサーチ インスティチュート 反応性非天然アミノ酸遺伝コード付加
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2006332809A1 (en) 2005-12-30 2007-07-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
EP2780463A4 (en) 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3004062B1 (en) 2013-05-24 2017-07-19 SynAffix B.V. Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
EP3650038A1 (en) 2013-06-19 2020-05-13 Massachusetts Institute of Technology In vivo targeting of cells with ligand-conjugated particles
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3097080A1 (en) 2014-01-24 2016-11-30 SynAffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
PT3134123T (pt) 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
JP7299021B2 (ja) 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
RS62040B1 (sr) * 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
EP4631529A3 (en) 2016-06-28 2026-03-11 Ventana Medical Systems, Inc. Application of click chemistry for signal amplification in ihc and ish assays
EP3272864A1 (en) 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
CA3061467A1 (en) 2017-04-28 2019-10-24 Ajinomoto Co., Inc. Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
AU2018337671B2 (en) 2017-09-19 2021-03-04 Paul Scherrer Institut Transglutaminase conjugation method and linker
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたil-2 fc融合タンパク質
US11970537B2 (en) 2017-12-26 2024-04-30 Nanjing GenScript Biotech Co., Ltd. Fusion protein dimer using antibody Fc region as backbone and use thereof
JP7102670B2 (ja) 2018-01-25 2022-07-20 アイ-エムエービー バイオファーマ ユーエス リミテッド 抗pd‐l1抗体とil‐7との融合
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
CN108503714A (zh) 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
EP4406975A3 (en) 2018-06-14 2024-11-13 Ajinomoto Co., Inc. Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
JP7413999B2 (ja) 2018-06-14 2024-01-16 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
AU2019288496B2 (en) 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
US12522640B2 (en) 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
WO2020061142A1 (en) 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3117853A1 (en) 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions
JPWO2020090979A1 (ja) 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
TW202034945A (zh) 2018-12-21 2020-10-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人白細胞介素2變體或其衍生物
CN113613679A (zh) 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法
KR20220009380A (ko) 2019-05-17 2022-01-24 선전 엔듀어링 바이오테크 리미티드 표적 면역요법을 위한 절단 가능한 사이토카인이 있는 이중특이적 t-세포 연계체
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
EP4013775A1 (en) 2019-08-12 2022-06-22 Askgene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
AU2020329933A1 (en) 2019-08-15 2022-03-24 Cytimm Therapeutics, Inc. Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
CN110642934B (zh) 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US11648296B2 (en) 2019-12-13 2023-05-16 Synthekine, Inc. IL-2 orthologs and methods of use
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
CA3162320A1 (en) 2019-12-23 2021-07-01 Alexander V. SHIROKOV Methods of preparing n6-((2-azidoethoxy)carbonyl)lysine
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
AR121713A1 (es) 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes
CA3168460A1 (en) 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
KR102986821B1 (ko) 2020-04-22 2026-07-06 머크 샤프 앤드 돔 엘엘씨 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
AU2021402065A1 (en) 2020-12-17 2023-06-29 Boehringer Ingelheim International Gmbh Bifunctional anti-pd1/il-7 molecules
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
JP2024504372A (ja) 2021-01-22 2024-01-31 エルピス・バイオファーマシューティカルズ 抗pd-l1モノクローナル抗体及びインターロイキン15(il-15)、インターロイキン15受容体15アルファまたはインターロイキン2との融合タンパク質

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515778A (ja) * 2009-01-21 2012-07-12 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2020521452A (ja) * 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US20210155665A1 (en) * 2017-07-24 2021-05-27 Eth Zurich Method for preparing interleukin-2 or interleukin-2 analogues
JP2021505156A (ja) * 2017-12-06 2021-02-18 パンディオン・オペレーションズ・インコーポレイテッド 標的化免疫寛容
WO2020236875A1 (en) * 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
WO2020242884A1 (en) * 2019-05-24 2020-12-03 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
WO2021011353A1 (en) * 2019-07-12 2021-01-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
WO2021021606A1 (en) * 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
WO2021076805A1 (en) * 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURAR, C.E., ET AL.: ""Chemical synthesis of interleukin-2 and disulfide stabilizing analogues."", ANGEW. CHEM. INT. ED., vol. 59, no. 22, JPN6026019007, 15 May 2020 (2020-05-15), pages 8425 - 8429, ISSN: 0005858325 *

Also Published As

Publication number Publication date
KR20240034221A (ko) 2024-03-13
CA3222357A1 (en) 2023-01-12
US12173062B2 (en) 2024-12-24
US20230303649A1 (en) 2023-09-28
WO2023281483A1 (en) 2023-01-12
WO2023281485A1 (en) 2023-01-12
US20230183331A1 (en) 2023-06-15
AU2022306974A1 (en) 2024-01-04
EP4367132A1 (en) 2024-05-15
EP4366779A1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
US12521441B2 (en) Modified IL-2 polypeptides and uses thereof
US20230303649A1 (en) Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US10265416B2 (en) Compositions for generation of immune tolerance to specific antigens
JP5431874B2 (ja) ポリエチレングリコール−grf結合体の部位特異的調製方法
US20220056091A1 (en) Modified il-18 polypeptides and uses thereof
US20230357342A1 (en) Modified il-18 polypeptides
JP2024526298A (ja) チェックポイント阻害剤とil-2とのコンジュゲート、およびその使用
NZ722352A (en) Erythrocyte-binding therapeutics
US20240417436A1 (en) Conditionally activated immunocytokines and methods of use
KR20240041378A (ko) 체크포인트 억제제와 il-2의 접합체 및 이의 용도
CN117616036A (zh) 用于治疗炎性疾病和自身免疫性疾病的修饰的il-2多肽
US20240424127A1 (en) Il-7 polypeptides, immunocytokines comprising same, and uses thereof
JP2019518714A (ja) タクロリムスのコンジュゲート、その組成物およびその使用
AU2021386899B2 (en) Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
WO2025083205A1 (en) Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260513